C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273)
12/2004
12/30/2004	US20040265797 Peptide ligands of the urokinase receptor
12/30/2004	US20040265280 Phoma sp. SANK 13899 (FERM BP-6851) strain; produce fungicide through fermentation process; obtained from a soil sample collected in Chichi-island, Ogasawara-mura, Tokyo
12/29/2004	WO2004113535A1 Synuclein mutant having anticoagulant effect
12/29/2004	WO2004113530A1 Polynucleotide for synthesis of labeled protein
12/29/2004	WO2004113378A2 Control of lactation and peptides therefore
12/29/2004	WO2004113368A1 Cyclic lipopeptides
12/29/2004	WO2004112572A2 Monitoring immunologic, hematologic and inflammatory diseases
12/29/2004	WO2003101393A3 Antibacterial compounds and methods for treating gram positive bacterial infections
12/29/2004	WO2003045984A3 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
12/29/2004	EP1491553A1 Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumours
12/29/2004	EP1491552A2 Method and apparatus for the microwave-assisted peptide synthesis
12/29/2004	EP1491236A1 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
12/29/2004	EP1490681A2 Peptide screen
12/29/2004	EP1490481A2 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
12/29/2004	EP1490396A2 Immunogenic hiv peptides for use as reagents and vaccines
12/29/2004	EP1490110A2 Anti-alpha v beta 6 antibodies
12/29/2004	EP1490089A1 Peptides selectively lethal to malignant and transformed mammalian cells
12/29/2004	EP1490054A2 Hemiasterlin derivatives and uses thereof in the treatment of cancer
12/29/2004	EP1343516A4 Analogues of thiocoraline and be-22179
12/29/2004	EP0996709B1 Inhibitors of cellulolytic, xylanolytic and beta-glucanolytic enzymes
12/29/2004	CN1558772A Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone
12/29/2004	CN1558770A Method of preventing cell death using segments of neural thread proteins
12/29/2004	CN1558762A Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer
12/29/2004	CN1182154C Novel dolastatin derivatives, their preparation and use
12/29/2004	CN1182153C Novel dolastatin derivatives, their preparation and use
12/29/2004	CN1181886C Application of TNF-derived peptides in the treatment of oedema
12/29/2004	CA2529045A1 Monitoring immunologic, hematologic and inflammatory diseases
12/28/2004	US6835808 Anti-heparin peptides
12/28/2004	US6835753 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt
12/28/2004	US6835382 Ii peptide therapeutics to enhance antigen presentation
12/23/2004	WO2004111240A2 Sequence for the bacillomycin d synthesis in bacillus amyloliquefaciens fzb42
12/23/2004	WO2004111192A2 Targeted delivery to legumain-expressing cells
12/23/2004	WO2004111084A2 Peptides enhancing ceh activity or inhibiting acat activity, pharmaceutical compositions comprising these peptides and their use in the treatment of atherosclerosis
12/23/2004	WO2004111078A2 Compounds that modulate the glucagon response and uses thereof
12/23/2004	WO2004111075A2 Alternative reading frame polypeptides for treatment
12/23/2004	WO2004110390A2 Anti-cd74 immunoconjugates and methods
12/23/2004	WO2004024182A3 Method for isolating hepatitis c virus peptides
12/23/2004	WO2003106692A3 Methods for the identification of all-antigens and their use for cancer therapy and transplantation
12/23/2004	WO2003106491A3 Cell penetrating peptides
12/23/2004	WO2003083436A3 Fibrinogen binding moieties
12/23/2004	US20040260069 Modified anti-tnf aplha antibody
12/23/2004	US20040260059 [microwave-assisted peptide synthesis]
12/23/2004	US20040259807 Monocyte locomotion inhibitory factor
12/23/2004	US20040259805 Stimulant of milk ejection; contraction; stability
12/23/2004	US20040259801 Ion exchanging a peptide; then salt formation; therapy for benign prostate hyperplasia; endometriosis
12/23/2004	US20040259800 Apoptosis of rectum and prostate cancer
12/23/2004	US20040259798 Drugs; integrin antagonist; antiinflammatory agents; leukemia therapy
12/23/2004	US20040259786 Method of transporting a chimeric hybrid molecule across the blood brain barrier
12/23/2004	US20040259782 Structural formulas based on the repetitive motifs of salivary proline rich proteins mucin and collagen designed to modulate cell and tissue growth division and differentiation
12/23/2004	US20040259775 Receptor ligand; for opiods; analgesics, anxiolytic agents, drug abuse, cognition activators
12/23/2004	US20040259773 Viricide peptide; nucleic acids encoding cyclic peptide
12/23/2004	US20040259126 MN gene and protein
12/23/2004	US20040258680 Methos of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogoues, isoforms and other derivatives
12/23/2004	US20040258619 Diaminedioxime radiometal complexes
12/23/2004	DE10325049A1 New peptide derivatives containing cell-adhesion molecule and phosphonate-containing anchor component, useful for treating disorders associated with implants, are inhibitors of integrins
12/23/2004	DE10235248B4 Fusionsprotein mit verstärkter in vivo-Aktivität von Erythropoietin Fusion protein with enhanced in vivo activity of erythropoietin
12/23/2004	CA2765196A1 Microwave-assisted peptide synthesis
12/23/2004	CA2563361A1 Cell permeable conjugates of peptides for inhibition of protein kinases
12/23/2004	CA2536357A1 Targeted delivery to legumain-expressing cells
12/23/2004	CA2531890A1 Peptides enhancing ceh activity or inhibiting acat activity for treating atherosclerosis
12/23/2004	CA2529496A1 Anti-cd74 immunoconjugates and methods
12/23/2004	CA2514288A1 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
12/22/2004	EP1488364A1 Method and system to build optimal models of 3-dimensional molecular structures
12/22/2004	EP1488011A2 Method of isolating binding peptides from a combinatorial phage display library and peptides produced thereby
12/22/2004	EP1487872A1 Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
12/22/2004	EP1487870A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
12/22/2004	EP1487776A1 Acid and ester compounds and methods of using the same
12/22/2004	EP1487762A1 Radiofluorination methods
12/22/2004	EP1487493A2 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
12/22/2004	CN1181096C Cyclic hexapeptide somatostatin analogues
12/22/2004	CN1181092C Conjugates useful in treatment of prostate cancer
12/22/2004	CN1181091C Factor Xa inhibitors
12/22/2004	CN1180840C Cyclosphorin-containing soft capsule preparation
12/21/2004	US6833436 Short peptides which selectively modulate the activity of serine/threonine kinases
12/21/2004	US6833382 Streptogramins and method for preparing same by mutasynthesis
12/21/2004	CA2390358C Process for rapid solution synthesis of peptides
12/16/2004	WO2004108938A2 Peptide ligands of dendritic cells for nucleic acid vector targeting
12/16/2004	WO2004108757A2 Antimicrobial polypeptides
12/16/2004	WO2004108756A2 Sars coronavirus peptides and uses thereof
12/16/2004	WO2004050685A3 Antifungal therapeutic agents
12/16/2004	WO2004014940A3 PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR ß PROTEINS
12/16/2004	WO2004011487A8 Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity
12/16/2004	WO2003066666A3 Compositions and methods for treatment of vitamin d deficiency
12/16/2004	US20040254342 Substrates and assays for beta-secretase
12/16/2004	US20040254341 Human aspartyl protease peptide for use in identifying modulators for treatment and prevention of neurodegenerative and nervous system disorders; enzyme inhibitors
12/16/2004	US20040254339 Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours
12/16/2004	US20040254338 Melanin-concentrating hormone antagonists
12/16/2004	US20040254120 Stimulating high density lipoproteins; osteoporosis; detoxification
12/16/2004	US20040254117 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
12/16/2004	US20040254116 Contactor tissue with transforming growth factor kinase receptors; modulate cell proliferation
12/16/2004	US20040254114 Genetic engineering
12/16/2004	US20040254106 Modified factor ix
12/16/2004	US20040254099 Compounds and methods for modulating beta-catenin mediated gene expression
12/16/2004	US20040253706 Substrates and assays for beta-secretase
12/16/2004	US20040253665 Novel peptide-producing enzyme, microbe producing the enzyme and method for dipeptide synthesis using them
12/16/2004	US20040253612 Selection of proteins using RNA-protein fusions
12/16/2004	US20040253248 Substance P-saporin (SP-SAP) conjugates and methods of use thereof
12/16/2004	US20040253247 Conjugate comprising a peptide having an engineered amino acid sequence capable of binding a plasma protein, said peptide conjugated to the therapeutic or diagnostic substance, wherein elimination half time of conjugate exceeds that of unconjugated therapeutic or diagnostic substance; peptide ligands
12/16/2004	US20040253240 immunogens used to induce immune response against specific epitopes of apolipoproteins; prophylaxis of atherosclerosis; immunotherapy
12/16/2004	US20040253182 Pathological tissue detection and treatment employing targeted benzoindole optical agents

1 ... 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 ... 423